<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01128699</url>
  </required_header>
  <id_info>
    <org_study_id>VESC# 2010-142</org_study_id>
    <nct_id>NCT01128699</nct_id>
  </id_info>
  <brief_title>Ahmed Valve Glaucoma Implant With Adjunctive Subconjunctival Bevacizumab in Refractory Glaucoma</brief_title>
  <official_title>Ahmed Valve Glaucoma Implant With Adjunctive Subconjunctival Bevacizumab in Refractory Glaucoma: a Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanak Eye Surgery Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanak Eye Surgery Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to demonstrate the efficacy and safety of subconjunctival injection of
      Avastin as an adjunctive therapy for Ahmed valve glaucoma implant in patients with refractory
      glaucoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Several studies have revealed evidences on the substantial role of Vascular endothelial
      growth factor-A (VEGF-A) in enhancing neovascularization processes. Some studies have shown
      the efficacy of intravitreal Avastin in reducing level of VEGF-A to improve NVG. On the other
      hand, recent pathological studies demonstrated that neutralization of VEGF reduced
      vascularity and decreased scar formation during wound healing, showing that VEGF strongly
      influence scar tissue formation. This may reduce the formation of encapsulated cyst after
      glaucoma surgeries and thus might improve the surgical success rate. The effect of
      subconjunctival bevacizumab as an adjunctive therapy in filtering glaucoma surgeries has been
      recently illustrated.

      We aim to demonstrate the efficacy and safety of subconjunctival injection of Avastin as an
      adjunctive therapy for Ahmed valve glaucoma implant in patients with refractory glaucoma.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2010</start_date>
  <completion_date type="Anticipated">July 2011</completion_date>
  <primary_completion_date type="Anticipated">May 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in intraocular pressure (IOP)</measure>
    <time_frame>12 months</time_frame>
    <description>To demonstrate the efficacy and safety of subconjuctival injection of Avastin as an adjunctive therapy for Ahmed valve glaucoma implant in patients with refractory glaucoma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surgical failure</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in intraocular pressure</measure>
    <time_frame>day 1, week 1, and months 1, 3, 6, 9</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Refractory Glaucoma</condition>
  <arm_group>
    <arm_group_label>ISA+AVI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>injection of intraoperative subconjunctival Avastin as an adjunct to Ahmed valve implant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AVI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ahmed valve implant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Subconjunctival Avastin</intervention_name>
    <description>Intraoperative Subconjunctival Avastin 1.25mg; single dose as an adjunct to 184 mm2 surface area Ahmed Glaucoma Valve (AGV Model FP7; New World Medical Inc., Rancho Cucamonga, California, USA)</description>
    <arm_group_label>ISA+AVI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ahmed Valve implant</intervention_name>
    <description>184 mm2 surface area Ahmed Glaucoma Valve (AGV Model FP7; New World Medical Inc., Rancho Cucamonga, California, USA)</description>
    <arm_group_label>AVI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of refractory glaucoma defined as uncontrolled IOP (&gt; 21 mm Hg)
             despite maximal antiglaucoma medication, previously failed surgical treatment, or a
             combination thereof

        Exclusion Criteria:

          -  No light perception

          -  elevated IOP associated with silicone oil

          -  previous glaucoma drainage device implantation in the same eye

          -  previous cyclodestructive treatment

          -  increased risk of endophthalmitis (e.g., active adnexal and ocular surface infection,
             immunosuppression, or immunodeficiency, including the use of systemic steroids)

          -  posterior segment disorders, or pre-existing ocular comorbidities (e.g., pterygium,
             phacodonesis, corneal opacity, or corneal endothelial dystrophies).

        Only 1 eye per patient was included in this trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nariman Nassiri, MD</last_name>
    <phone>(+98) 21 8877 4143</phone>
    <email>drnassirin@sbmu.ac.ir</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vanak Eye Surgery Center</name>
      <address>
        <city>Tehran</city>
        <zip>1517973813</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nariman Nassiri, MD</last_name>
      <phone>(+98) 21 8877 4143</phone>
      <email>drnassirin@sbmu.ac.ir</email>
    </contact>
    <investigator>
      <last_name>Nader Nassiri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nariman Nassiri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mercede Majdi-N, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arash Mazouri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nazanin Rahman-A, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2010</study_first_submitted>
  <study_first_submitted_qc>May 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2010</study_first_posted>
  <last_update_submitted>May 21, 2010</last_update_submitted>
  <last_update_submitted_qc>May 21, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 24, 2010</last_update_posted>
  <responsible_party>
    <name_title>Nader Nassiri</name_title>
    <organization>Associate Professor, Department of Ophthalmology, Imam Hossein Medical Center, Shaheed Beheshti University of Medical Sciences, Tehran, Iran</organization>
  </responsible_party>
  <keyword>Ahmed valve</keyword>
  <keyword>Neovascular Glaucoma</keyword>
  <keyword>Uveitic glaucoma</keyword>
  <keyword>Failed glaucoma</keyword>
  <keyword>VEGF-A</keyword>
  <keyword>Intraocular pressure</keyword>
  <keyword>Subconjunctival Avastin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

